Gian Marco Ghiggeri
Nephrology — Istituto Giannina Gaslini, Italy
Gian Marco Ghiggeri
LeadR Profile
Nephrology
Subspecialties: Immunology - Transplantation - Pediatrics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1989 - 2026
Number : 531
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Editorial: Case reports in autoimmune and autoinflammatory disorders, volume II. vasculitis, immunotherapy, autoimmunity | Front Immunol | 2026 | 0 |
| Extending the concept of 'exhausted T-cells' to idiopathic nephrotic syndrome. kidney diseases, cells, nephrotic syndrome | Pediatr Nephrol | 2026 | 0 |
| Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab. calcineurin, kidney, rituximab, nephrotic syndrome, steroids, child | Kidney Int Rep | 2026 | 0 |
| The landscape of serum autoantibodies in lupus nephritis. proteinuria, autoantibodies, serum, antibodies, lupus nephritis, biomarkers, signs and symptoms, histones, nephritis, autoimmunity | Autoimmun Rev | 2026 | 0 |
| Efficacy and Safety of Rituximab Therapy to Sustain Remission in Young Children With Childhood Nephrotic Syndrome. safety, nephrosis, lipoid, neutropenia, aged, rituximab, nephrotic syndrome, therapeutics, infections, child | Kidney Int Rep | 2026 | 0 |
Clinical Studies 11
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 14
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy of Anti CD20 Ab Associated With Anti CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome NCT05704400 — cells, saline solution, antibodies, pharmaceutical preparations, rituximab, nephrotic syndrome, therapeutics, nephrosis, biosimilar pharmaceuticals | Phase 2 | Recruiting | 2023 |
LeadR Networks
Main global connection map